A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 582 participants.
Also called NCT04880850
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 582 participants
- Sponsor
- Registry
-
NCT04880850 -
2020-000474-16
-
- Main results
- Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, India, Italy, Japan, Mexico, Netherlands, Romania, Russia
- Registry status
- Completed
Technical summary
Registry record NCT04880850. Randomized; no masking; primary purpose treatment. Start 2021-05-14 (actual); primary completion 2022-06-16 (actual). Results posted on 2025-07-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
- Acronym
- ONWARDS 4
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin icodec
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- Insulin aspart
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04880850- Content hash
f6293ecefa3dcbd7111c684053895c600f29aa548a462a469d4b1ec74a6205c3